United Therapeutics Sells Priority-Review Voucher to AbbVie for $350 Million
August 19 2015 - 7:15AM
Dow Jones News
By Chelsey Dulaney
United Therapeutics Corp. has agreed to sell a voucher meant to
speed approval for rare pediatric disease treatments to AbbVie Inc.
for $350 million.
United Therapeutics received the voucher when its neuroblastoma
treatment Unituxin was approved by the U.S. Food and Drug
Administration.
The voucher is part of an incentive program established by the
FDA to encourage development of drugs for rare pediatric diseases.
The voucher entitles the holder to ask the FDA for priority review
of a drug application that would otherwise get a standard review.
That could shorten the review process to six months from the
standard 10 months.
In July, Retrophin Inc. sold a priority-review voucher to French
drug maker Sanofi SA for a total consideration of about $245
million.
Write to Chelsey Dulaney at Chelsey.Dulaney@wsj.com
Access Investor Kit for Sanofi
Visit
http://www.companyspotlight.com/partner?cp_code=P479&isin=FR0000120578
Access Investor Kit for Sanofi
Visit
http://www.companyspotlight.com/partner?cp_code=P479&isin=US80105N1054
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
August 19, 2015 07:00 ET (11:00 GMT)
Copyright (c) 2015 Dow Jones & Company, Inc.
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Apr 2023 to Apr 2024
